Evelyn Warner, Author at Labiotech.eu

About

Ex-Editor. Recovering organic chemist. Chagrined member of the Brooklyn-Berlin exchange program. Proud parent of a majestic domestic long hair.

Articles by Evelyn Warner

News and Trends 14 Sep 2016

This French Startup brings Gene Therapy to Neurodegenerative Diseases

There were many exciting developments for CNS disease treatments last year, and now a French biotech is winding up to add gene therapy to the mix. BrainVectis just closed its Series A round with €1M. Paris-based BrainVectis wants to apply some of the hottest technology in biotech, gene therapy, to neurodegenerative disease, and it just […]

September 14, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 14 Sep 2016

Novartis invests in Irish Upstart tackling Chronic Inflammation

Dublin-based Inflazome has made a splashy debut by closing Series A with €15M. The company will use these funds to develop therapies targeting inflammasome-based chronic diseases. Chronic inflammation might sound like a minor livable irritation, but it can be deadly. Think Multiple Sclerosis, Rheumatoid Arthritis, and Lupus. It’s also one of the most lucrative fields […]

September 14, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 13 Sep 2016

The next generation of Antibiotics could be Bacteriophages

One of the last remaining bastions for organic chemists in pharmaceuticals is in antibiotic development. It is now under fire from a partnership of academic and industrial microbiologists, who are developing bacteriophages into antibacterial therapies. A team of researchers headed by Dr. Janet Neal and Prof. Martha Clokie at the University of Leicester demonstrated the […]

September 13, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 13 Sep 2016

Horizon Pharma successfully negotiates Acquisition of US Competitor for €712M

Perhaps having learned from its Depomed debacle last year, Horizon Pharma has lined up a successful acquisition of another competitor, Raptor Pharmaceuticals, for €712M ($800M). Last summer, the Irish company, Horizon Pharma, wouldn’t take no for an answer in its overtures to acquire Depomed, an American speciality pharmaceutical company. It was rejected not once but twice, […]

September 13, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 13 Sep 2016

Reviewing CRISPR, the Scientific Discovery of the Century

What’s happening with CRISPR these days? Another company just filed for an IPO, documents relevant to CRISPR patent war have come to light, research is moving forward, and the therapy is one step closer to the clinic. In this review, we discuss why the exciting new technology and the drama surrounding it: big money, no clinical […]

September 13, 2016 - 8 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming – the only question was, when would CRISPR Therapeutics file for an IPO? News arrived today that the company had finally applied to the US […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

Sanofi & Google Joint Venture could Revolutionize Diabetes

Sanofi and Verily, formerly Google Life Sciences, have signed a deal to form a €444M joint venture, Onduo. Its aim is to integrate medicine and microelectronics to tackle diabetes. Steve Jobs prophesied that “the biggest innovations of the twenty-first century will be the intersection of biology and technology,” and it appears that Verily, a division of […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 10 Sep 2016

This Dutch BioArtist could be the Mistress of Natural Forces

Roos Meerman is a force to be reckoned with in the BioArt world – she has been racking up awards and just took home the 2016 BioArt & Design Award. Her work focuses on the manipulation of materials with natural forces like sound and temperature. Roos Meerman is a Dutch bioartist whose work on natural […]

September 10, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 9 Sep 2016

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

A German biotech has surfaced with a promising new drug for traumatic brain injury: vasopharm’s Nitrous Oxide Synthase inhibitor is starting Phase III. In news from the novel and obscure, someone has taken an interest in Nitrous Oxide Synthase (NOS). That someone is vasopharm GmbH, a small German biopharmaceutical company interested in cerebrovascular diseases. The company has […]

September 9, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 8 Sep 2016

Allergan seizes visionary Optogenetic Therapy from US Startup

Allergan is diving into gene therapy with the acquisition of RetroSense Therapeutic’s new early clinical candidate, RST-001. The drug aims to remedy Retinitis Pigmentosa, which affects between 13 and 44 in 100k people worldwide. Allergan has just acquired RetroSense Therapeutics as part of their ongoing effort in eye care. The core of the deal was […]

September 8, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 7 Sep 2016

Building Life from DNA Legos, a Review of Synthetic Biology

It sounds like a lot of fun, but DNA legos are serious: they represent the core concept of synthetic biology, a field with the potential to solve major issues in public health, society and the environment. Here’s a survey of this exciting new area of development. Major thanks to Eshna Gogia at Helixworks for letting us use her article as a source! […]

September 7, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 7 Sep 2016

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

An American outfit from Third Rock Ventures, Fulcrum Therapeutics, has made a deal with Horizon to access its catalogue of genetic anomalies. The collaboration will target diseases arising from gene misregulation. Horizon Discovery has announced a collaboration with Fulcrum Therapeutics, launched earlier this year by Third Rock Ventures, to target diseases caused by gene regulation malfunction. Fulcrum […]

September 7, 2016 - 2 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Evelyn Warner

About

Articles by Evelyn Warner

This French Startup brings Gene Therapy to Neurodegenerative Diseases

Novartis invests in Irish Upstart tackling Chronic Inflammation

The next generation of Antibiotics could be Bacteriophages

Horizon Pharma successfully negotiates Acquisition of US Competitor for €712M

Reviewing CRISPR, the Scientific Discovery of the Century

CRISPR Therapeutics applies to go Public in another Massive IPO

Sanofi & Google Joint Venture could Revolutionize Diabetes

This Dutch BioArtist could be the Mistress of Natural Forces

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

Allergan seizes visionary Optogenetic Therapy from US Startup

Building Life from DNA Legos, a Review of Synthetic Biology

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

Subscribe to our newsletter to get the latest biotech news!